Lineage Cell Therapeutics Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 77

Employees

  • Stock Symbol
  • LCTX

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $0.77
  • (As of Friday Closing)

Lineage Cell Therapeutics General Information

Description

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Contact Information

Formerly Known As
BioTime
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2173 Salk Avenue
  • Suite 200
  • Carlsbad, CA 92008
  • United States
+1 (442)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
ASE
Vertical(s)
Corporate Office
  • 2173 Salk Avenue
  • Suite 200
  • Carlsbad, CA 92008
  • United States
+1 (442)

Lineage Cell Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lineage Cell Therapeutics Stock Performance

As of 20-Nov-2026, Lineage Cell Therapeutics’s stock price is $0.77. Its current market cap is $195M with 253M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.77 $0.82 $0.77 - $1.99 $195M 253M 1.63M

Lineage Cell Therapeutics Financials Summary

As of 30-Sep-2026, Lineage Cell Therapeutics has a trailing 12-month revenue of $10.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 192,056 345,538 79,406 151,026
Revenue 10,836 14,556 9,499 8,945
EBITDA (3,708) (69,639) (19,688) (24,219)
Net Income 1,753 (63,533) (18,609) (21,486)
Total Assets 100,110 112,584 113,218 101,019
Total Debt 2,029 2,419 2,514 2,952
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lineage Cell Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lineage Cell Therapeutics‘s full profile, request access.

Request a free trial

Lineage Cell Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization
Drug Discovery
Carlsbad, CA
77 As of 2025

Somerville, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lineage Cell Therapeutics Competitors (53)

One of Lineage Cell Therapeutics’s 53 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Lisata Therapeutics Corporation Basking Ridge, NJ
Orgenesis Corporation Germantown, MD
You’re viewing 5 of 53 competitors. Get the full list »

Lineage Cell Therapeutics Patents

Lineage Cell Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026161581-A1 Methods of characterizing cell populations for auditory conditions Pending 23-Jan-2025
AU-2025212536-A1 Combination methods comprising cell therapy and cochlear implant Pending 24-Jan-2024
WO-2025160249-A1 Combination methods comprising cell therapy and cochlear implant Pending 24-Jan-2024
WO-2024102777-A2 Compositions and method for expansion of embryonic stem cells Inactive 08-Nov-2022
WO-2024102777-A3 Compositions and method for expansion of embryonic stem cells Inactive 08-Nov-2022 C12N5/0639
To view Lineage Cell Therapeutics’s complete patent history, request access »

Lineage Cell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lineage Cell Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lineage Cell Therapeutics‘s full profile, request access.

Request a free trial

Lineage Cell Therapeutics Investments & Acquisitions (8)

Lineage Cell Therapeutics’s most recent deal was a Merger/Acquisition with Neuroairmid Therapeutics for . The deal was made on 13-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neuroairmid Therapeutics 13-Nov-2026 Merger/Acquisition Drug Delivery
Asterias Biotherapeutics 11-Mar-2019 Merger/Acquisition Drug Discovery
Cell Cure Neurosciences 18-Jun-2017 Secondary Transaction - Private Biotechnology
Cell Cure Neurosciences 16-Feb-2016 Secondary Transaction - Private Biotechnology
Geron Corporation (Stem Cell Assets) 01-Oct-2013 Merger/Acquisition Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Lineage Cell Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.87 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lineage Cell Therapeutics’s complete esg history, request access »

Lineage Cell Therapeutics Exits (1)

Lineage Cell Therapeutics’s most recent exit was on 24-Mar-2011 from Recyte Therapeutics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Recyte Therapeutics 24-Mar-2011 Completed
To view Lineage Cell Therapeutics’s complete exits history, request access »

Lineage Cell Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cell Cure Neurosciences Jerusalem, Israel 2005
Neuroairmid Therapeutics Irvine, CA

Lineage Cell Therapeutics FAQs

  • When was Lineage Cell Therapeutics founded?

    Lineage Cell Therapeutics was founded in 1990.

  • Where is Lineage Cell Therapeutics headquartered?

    Lineage Cell Therapeutics is headquartered in Carlsbad, CA.

  • What is the size of Lineage Cell Therapeutics?

    Lineage Cell Therapeutics has 77 total employees.

  • What industry is Lineage Cell Therapeutics in?

    Lineage Cell Therapeutics’s primary industry is Drug Discovery.

  • Is Lineage Cell Therapeutics a private or public company?

    Lineage Cell Therapeutics is a Public company.

  • What is Lineage Cell Therapeutics’s stock symbol?

    The ticker symbol for Lineage Cell Therapeutics is LCTX.

  • What is the current stock price of Lineage Cell Therapeutics?

    As of 20-Nov-2026 the stock price of Lineage Cell Therapeutics is $0.77.

  • What is the current market cap of Lineage Cell Therapeutics?

    The current market capitalization of Lineage Cell Therapeutics is $195M.

  • What is Lineage Cell Therapeutics’s current revenue?

    The trailing twelve month revenue for Lineage Cell Therapeutics is $10.8M.

  • Who are Lineage Cell Therapeutics’s competitors?

    Genetix Biotherapeutics, Allogene Therapeutics, Apellis Pharmaceuticals, Lisata Therapeutics, and Orgenesis are some of the 53 competitors of Lineage Cell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process